- Home
- DVAX
as 11-15-2024 4:00pm EST
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 1.5B | IPO Year: | 2004 |
| Target Price: | $22.00 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.15 | EPS Growth: | -67.55 |
| 52 Week Low/High: | $9.74 - $15.01 | Next Earning Date: | 11-07-2024 |
| Revenue: | $260,810,000 | Revenue Growth: | -27.79% |
| Revenue Growth (this year): | 23.13% | Revenue Growth (next year): | 19.60% |
Latest Dynavax Technologies Corporation News
DVAX Breaking Stock News: Dive into DVAX Ticker-Specific Updates for Smart Investing
Argus Research
4 days ago
DVAX: Raising target price to $11.00
Zacks
5 days ago
Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why
Zacks
5 days ago
Wall Street Analysts Predict an 88.32% Upside in Dynavax Technologies (DVAX): Here's What You Should Know
MT Newswires
5 days ago
Dynavax Technologies to Repurchase $100 Million From Goldman Sachs
PR Newswire
5 days ago
Dynavax Announces $100 Million Accelerated Share Repurchase Program
Simply Wall St.
6 days ago
Dynavax Technologies Corporation Just Recorded A 9.1% EPS Beat: Here's What Analysts Are Forecasting Next
Simply Wall St.
7 days ago
Dynavax Technologies Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
GuruFocus.com
8 days ago
Dynavax Technologies Corp (DVAX) Q3 2024 Earnings Call Highlights: Record Hep B Sales and ...
Compare DVAX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DVAX Dynavax Technologies Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.